2023-05-30 09:03:45 ET
- HeartBeam ( NASDAQ: BEAT ) is trading 35% higher premarket after it had entered into a strategic alliance with Samsung to revolutionize cardiac diagnostics.
- The partnership combines HeartBeam's expertise in cardiac assessment and monitoring with Samsung's technologies.
- The companies would integrate HeartBeam's telehealth platform and Samsung's FDA-cleared arrhythmia detection tool for cardiac diagnostics for patients at home.
- HeartBeam's recent acquisition of LIVMOR's assets strengthens its position in the cardiac technology sector.
- The collaboration focuses on improving healthcare for veterans and addressing major cardiac conditions.
- LIVMOR's Halo Atrial Fibrillation ( AF ) Detection System plays a significant role in the partnership.
- The collaboration has resulted in an FDA-cleared solution for Atrial Fibrillation detection using Samsung's Galaxy watch and tablet.
- The initiative aims to improve heart attack detection and enhance patient care outside of traditional medical settings.
- Press Release
For further details see:
HeartBeam forms strategic alliance with Samsung for cardiac diagnostics; shares surge 35%